Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lethal Alleles

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...

Toxic Reactions: Overview

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026

Same author

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Science translational medicine·2026

Same author

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Blood·2026

Same author

A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity.

Nature cancer·2026

Same author

Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia.

Blood·2026

Search research articles

Related Experiment Video

Updated: May 22, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

Katharin Shaw¹, René Bernards², Kimberly Stegmaier³

¹Broad Institute of MIT and Harvard, Cambridge, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Trends in Cancer

|May 20, 2025

Summary

Cancer cells exploit oncogenic hyperactivation, a vulnerability to targeted therapies. This activation lethality strategy offers a new way to treat cancer by inducing lethal pathway activation, overcoming resistance to current treatments.

Keywords:

activation lethality cancer genetics oncogene overdose signaling regulation targeted therapy therapeutic development

More Related Videos

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy

Published on: February 3, 2017

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

Related Experiment Videos

Last Updated: May 22, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy

Triggering Cell Stress and Death Using Conventional UV Laser Confocal Microscopy

Published on: February 3, 2017

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Published on: October 28, 2022

Area of Science:

Oncology
Molecular Biology
Cancer Therapeutics

Background:

Cancer cells maintain survival by optimizing oncogenic signaling within a specific range.
Targeted therapies aim to suppress signaling below this optimal fitness zone.
Cancers possess a vulnerability to oncogenic hyperactivation, a strategy currently underutilized in clinics.

Purpose of the Study:

To explore oncogenic hyperactivation as a therapeutic strategy in cancer treatment.
To investigate the potential of inducing lethal pathway activation in cancer cells.
To address the limitations of current targeted therapies and overcome treatment resistance.

Main Methods:

Deep characterization of cancer genomes.
Unbiased screening approaches to identify targets.
Investigating small-molecule activators and inhibitors of negative regulators.

Main Results:

Cytotoxic hyperactivation is observed across diverse cancer types.
Multiple targets vulnerable to hyperactivation have been identified.
Inducing lethal pathway activation through small molecules shows promise.

Conclusions:

Exploiting cancer's intrinsic vulnerability to oncogenic hyperactivation offers a novel therapeutic strategy.
Activation lethality can expand the cancer treatment landscape and overcome resistance to targeted inhibition.
Clinical translation requires defining signaling thresholds, discovering biomarkers, and developing appropriate trial designs.